Trade names Glufast ATC code A10BX08 (WHO) PubChem CID 121891 | Routes of
administration By mouth (tablets) CAS Number 145375-43-5 Molar mass 315.41 g/mol | |
 | ||
AHFS/Drugs.com International Drug Names | ||
Mitiglinide (INN, trade name Glufast) is a drug for the treatment of type 2 diabetes.
Contents
Mitiglinide belongs to the meglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.
Pharmacology
Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive potassium KATP channels in pancreatic β cells.
Dosage
Mitiglinide is delivered in tablet form.
References
Mitiglinide Wikipedia(Text) CC BY-SA